People | May 17, 2024
Takeda appoints Annapurna Das as the General Manager, India Operations
Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines
Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines
EC grants conditional marketing authorization based on the EFFISAYIL trial
The company hopes to build on this momentum in the coming quarters and continue to focus on our key brands to drive sustainable profitable growth
CHMP positive opinion is based on evidence from the EFFISAYIL trial, the largest clinical trial in
Her appointment further strengthens the CDMO’s strategy to become the nutraceutical R&D hub for brands looking for agile partners with large scientific and development resources
Spesolimab is a monoclonal antibody that inhibits interleukin-36 (IL-36) signaling and is the first treatment specifically approved for the treatment of generalized pustular psoriasis flares
The procedures have been performed by Dr. Kaushal Pandey at P.D. Hinduja Hospital in Mumbai, India
Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks
Clinical improvements were consistent across patient subgroups including age, gender, ethnicity, and IL-36 gene mutation status
The NDA for Desidustat is based on positive data from the DREAM-ND and DREAM-D Phase 3 trials in patients with Chronic Kidney Disease (CKD) Not on Dialysis and Dialysis
Subscribe To Our Newsletter & Stay Updated
